Wegovy Results: What the STEP Trials Actually Show

Search "Wegovy results" and the numbers that come back are rarely just Wegovy's. Ozempic's smaller diabetes-trial figures, generic "semaglutide" averages pulled from compounding pharmacies, and Wegovy's own data all end up on the same results page, even though they come from different trials, different doses, and different approved uses. Only one program actually measured Wegovy itself: the STEP trials, built specifically around the 2.4mg dose the FDA approved for chronic weight management. That's where every number below comes from.

How much weight do people actually lose on Wegovy?

STEP 1 is the trial that got Wegovy approved, and it's still the cleanest answer to this question. Over 68 weeks, adults without diabetes taking the 2.4mg dose lost an average of 14.9% of their starting body weight, compared with 2.4% on placebo. That figure includes everyone assigned to the drug — people who didn't tolerate it well, people who stopped early, everyone — so it's a conservative read of what someone who stays on treatment and reaches the full dose tends to see.

An average also flattens a real spread of outcomes. In STEP 1, 86.4% of people on semaglutide lost at least 5% of their body weight — the threshold researchers generally use to call a weight-loss drug effective — against 31.5% on placebo. Some people land well above the 14.9% average, some land below it, and neither outcome is unusual on its own.

How long does it take for Wegovy to actually start working?

Semaglutide reaches peak blood levels within a day or two of a first injection, so in a strict sense it starts working almost immediately. But the dose you start on, 0.25mg, is built for tolerance, not treatment — it exists to let your gut adjust before the dose climbs into a range that actually suppresses appetite. The full Wegovy dosage chart walks through why the ladder is built that way and how long each step takes to climb.

Within that frame, a fairly consistent pattern shows up across people. Appetite tends to change first — smaller portions feel like enough, food thoughts quiet down — often within the first one to two weeks. The scale usually follows a few weeks behind that. Anything you'd call a visible change tends to show up later still, once the dose has moved past the starting tiers, generally somewhere in the eight-to-twelve-week range. Nausea, looser stools, and an appetite change that feels more like a stomach bug than a diet are common and expected during that early stretch, not a sign anything's gone wrong.

Wegovy before and after: a realistic month 1, month 3, month 6+ progression

Knowing the shape of the curve ahead of time makes the slow early stretch easier to sit through. The pacing below tracks the standard titration schedule, not a fixed calendar — holding a step longer for side effects pushes everything out further.

• Month 1, weeks 1–4: on the 0.25mg starting dose. Appetite is usually the first thing that shifts; the scale barely moves yet, and that's expected — this dose is doing tolerance work, not treatment work.
• Month 3, around week 12: the dose has typically climbed to 1mg. Loss tends to be gradual but consistent through here — consumer-health trackers commonly describe early-months pace as roughly 2% of body weight per month once the dose is actually working, though no single STEP publication reports a clean month-by-month curve the way it reports the 68-week endpoint.
• Month 6, around week 24: most people have reached or are close to the 2.4mg maintenance dose, which the standard schedule reaches by week 17. This is usually where the loss becomes unmistakable rather than gradual.
• Month 12 to roughly 16, week 68: this is where STEP 1 actually measured its headline number — an average of 14.9% of starting body weight, with the bulk of that loss already in place by this point.
• Beyond that: for people who've plateaued at 2.4mg, the newer 7.2mg step-up dose, studied in the STEP UP trial, averaged close to 21% of body weight lost at 72 weeks — evidence that a plateau at the standard dose isn't necessarily the ceiling.

How does Wegovy actually help you lose weight?

Wegovy works by mimicking GLP-1, a hormone your gut already releases after eating — semaglutide just makes the signal last about a week instead of a few minutes. That sustained signal slows digestion and quiets appetite in the brain, so the weight loss above comes from eating less over time, not from burning fat directly. How Wegovy actually works covers the full mechanism, what it's FDA-approved to treat, and how it differs from Ozempic and Zepbound.

How long do you have to stay on Wegovy — and does the weight come back if you stop?

STEP 1 didn't stop at 68 weeks. A subset of participants agreed to keep being followed after stopping both the drug and the structured lifestyle support that came with the trial. Within that group, on-treatment loss at week 68 ran a bit higher than the full trial's headline number — 17.3% rather than 14.9% — likely because people who stay in a trial's extension tend to be people who tolerated and stuck with treatment especially well.

What happened after they stopped is the number that actually answers this question. A year later, at week 120, that group had regained 11.6 percentage points of the weight they'd lost, leaving a net loss of 5.6% — still meaningfully below their starting weight, but a long way from where treatment had them. Only 48.2% still had at least 5% loss at that point, down from 86.4% while on treatment. The placebo group, who'd had almost nothing to lose in the first place, barely changed either way.

None of that is a failure of willpower. It's consistent with how the drug works in the first place: the appetite signal was doing the work, and removing the signal lets appetite drift back toward where it started. The honest read of STEP 1's own data is that Wegovy treats an ongoing condition, closer to blood-pressure medication than a course you finish and stop.

5 ways to increase your weight loss results on Wegovy

Trial averages describe the shape of the curve. What you actually do within that curve moves your own number.

• Reach and hold your maintenance dose. STEP UP found that people who stayed on 7.2mg through 72 weeks lost close to 21% on average, meaningfully more than the roughly 18% typically associated with the standard 2.4mg dose over the same stretch — the dose you actually stay on matters more than the dose written on the prescription pad on day one.
• Layer on structured behavioral support, not just the injection. STEP 1 paired semaglutide with standard diet-and-exercise counseling and averaged 14.9% loss at 68 weeks. STEP 3 tested the same 2.4mg dose against a much heavier support structure — 30 dietitian visits, a supervised low-calorie start, a built-in activity plan — and averaged 16% at the same 68-week mark, with 75% of participants reaching at least 10% loss versus 27% on placebo plus the same intensive support. That's not a randomized head-to-head between semaglutide alone and semaglutide plus coaching — it's two different trials with two different support levels — but the gap points the same direction as most GLP-1 research: more structure around the medication tends to add to it rather than compete with it.
• Prioritize protein and resistance training. A meaningful share of weight lost on any GLP-1 is lean muscle, not just fat — more consequential in your 40s and 50s, when estrogen decline is already working against muscle on its own. Our guide to GLP-1 and muscle loss in perimenopause covers what actually protects strength while the weight comes off.
• Stay consistent with the weekly shot. A missed or delayed dose interrupts the steady drug level these medications depend on — one of the few variables in the trials above that real life controls less tightly than a study protocol does.
• Consider the 7.2mg step-up if 2.4mg has plateaued. Wegovy HD, a 7.2mg strength cleared in 2026, exists specifically for this situation — not as a faster starting point, but as a further option once 2.4mg has stopped producing change. The dosage chart covers how that step fits into the broader ladder.

Why your results might look different in perimenopause or after menopause

The honest starting point here: Wegovy's original pivotal trials didn't track participants by menopausal status, so for years there wasn't a dedicated answer to this question — only extrapolation from what's known generally about estrogen, fat distribution, and insulin sensitivity in midlife. That changed with a 2026 post-hoc analysis of the STEP UP trial, presented at the European Congress on Obesity, which broke the 7.2mg results down specifically by reproductive stage.

Premenopausal women averaged 22.6% weight loss at 72 weeks. Perimenopausal women averaged 19.7%. Postmenopausal women averaged 19.8%. That's a real gap — a few percentage points, consistently in the same direction across both midlife groups — but it's not a different drug response. It's the same medication working against a body that's already shifted where it stores fat and how it handles insulin.

A separate, smaller strand of research adds a related wrinkle worth naming honestly rather than glossing over: a 2024 retrospective study of postmenopausal women on semaglutide found that those also using menopause hormone therapy lost more weight than those who weren't — about 16% versus 12% of body weight at 12 months, roughly a 30% relative difference. That's observational data from real-world patients, not a randomized trial, so it shows an association worth discussing rather than a proven cause. GLP-1 and menopause goes deeper into how the two treatments interact.

None of this changes what Wegovy is doing at the receptor level — GLP-1 biology doesn't know what decade you're in. What changes is the baseline it's acting against: fat that's already redistributed toward the abdomen, resting metabolism that's already drifted downward, insulin sensitivity already under more pressure. If you're not sure how much of what you're experiencing is perimenopause versus something else entirely, a quick symptom check can help sort that out before your next appointment.

Is a plateau on Wegovy normal, or has it stopped working?

Some plateau is simple physics: a smaller body needs fewer calories to maintain itself, so the eating pattern that produced steady loss early on eventually stops producing more of it. STEP 1's own data reflects this — the rate of loss was fastest in the first several months and gradually slowed as the trial went on, without fully stopping through week 68.

A stall at a stable, lower weight isn't the same thing as the drug failing. What's worth flagging for whoever's prescribing it is a different pattern: weight climbing back up on a dose that hasn't changed. That's not the plateau the trial data describes, and it's the point where a conversation about dose, timing, or what else might be going on is worth having sooner rather than later.

What actually determines your individual result?

Everything above points to the same conclusion: there's no single number that describes what Wegovy will do for you, because too many variables sit underneath the trial averages.

• The dose you reach and tolerate — STEP UP's gap between 2.4mg and 7.2mg shows this plainly
• How long you stay on it, since STEP 1's own extension shows what happens once treatment stops
• Whether structured behavioral support is layered on top, the difference STEP 1 and STEP 3 point toward
• Your starting metabolic and hormonal picture, including where you are in the menopause transition
• Plain consistency — missed doses and gaps reset parts of the curve described above
• Individual variation in receptor sensitivity and genetics that trial averages can't predict for any one person

What this costs, and where to start

The number that actually matters most for your own results is less about which pathway is cheapest and more about which one keeps you engaged through the slow early months — because the biggest driver of the numbers above wasn't price, it was staying on treatment long enough to reach a real maintenance dose.